Semaglutide vs Retatrutide: GLP-1 Peptides Head-to-Head

By NorthPeptide Research Team · April 6, 2026

If you have been following the GLP-1 space for more than a year, you have watched an unusual thing happen in science: a class of molecules that previously produced 5–8% weight loss in trials started producing 15%, then 22%, then nearly 30%. Each step forward was driven by adding more receptor targets to the molecule.

Semaglutide was the first drug to show that pharmacological weight loss could rival bariatric surgery for some patients. Retatrutide may push that ceiling even higher. This article compares them directly — mechanisms, clinical numbers, side effects, and what the data actually says about which direction metabolic research is heading.

The Core Difference: One Receptor vs Three

The simplest way to understand this comparison is to count the receptors.

Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, an incretin hormone your gut releases after eating. GLP-1 receptors sit in your pancreas, brain, and stomach. Activating them slows gastric emptying, suppresses appetite through hypothalamic circuits, and boosts insulin secretion in a glucose-dependent way (meaning it only releases insulin when blood sugar is already elevated — important for safety).

Retatrutide is a triple receptor agonist. It activates GLP-1, GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors simultaneously. Each additional pathway adds something the others do not:

• GIP receptor: Enhances insulin secretion further, modulates fat storage in adipose tissue, and may reduce some of the GI side effects associated with GLP-1 agonism alone.
• Glucagon receptor: Increases resting energy expenditure (your body burns more calories at rest), drives hepatic fat oxidation, and clears liver fat — a mechanism not available to semaglutide at all.

That glucagon component is the key differentiator. Glucagon traditionally raises blood sugar (the opposite of what you want in metabolic disease), but when glucagon receptor agonism is paired with GLP-1 and GIP activity, the blood sugar-raising effect is counterbalanced. What remains is the metabolic upside: thermogenesis and liver fat clearance.

Mechanism Comparison: How Each Peptide Works

Both peptides share the once-weekly subcutaneous injection schedule, the engineered resistance to rapid enzymatic degradation, and the core GLP-1 mechanism. But retatrutide layers two additional receptor interactions on top of that shared foundation.

Clinical Weight Loss Data: The Numbers

This is where the comparison gets concrete.

Semaglutide: STEP Trial Program

The STEP (Semaglutide Treatment Effect in People with Obesity) trials are the landmark dataset for semaglutide’s weight management effects. Key results from the program:

• STEP 1 (2021): 1,961 non-diabetic adults, BMI ≥30. Semaglutide 2.4 mg weekly + lifestyle intervention → 14.9% mean weight loss at 68 weeks vs 2.4% for placebo. About one-third of subjects lost ≥20% of body weight. (Wilding et al., NEJM 2021)
• STEP 2 (2021): Adults with type 2 diabetes → 9.6% mean weight loss at 68 weeks.
• STEP 3 (2021): Combined with intensive behavioral therapy → 16.0% mean weight loss.
• STEP 5 (2022): 2-year data → 15.2% sustained weight loss at 104 weeks with continued treatment.
• SELECT Trial (2023): 17,604 adults with overweight/obesity and established cardiovascular disease — semaglutide produced 20% reduction in major adverse cardiovascular events. (Lincoff et al., NEJM 2023)

Semaglutide’s cardiovascular outcomes data (SELECT) is a major differentiator from retatrutide — it has a proven mortality-relevant endpoint in a large trial. Retatrutide has a cardiovascular outcomes trial underway but no completed CVOT data yet.

Retatrutide: Phase 2 and TRIUMPH Phase 3

Retatrutide’s pivotal data set is newer but striking:

• Phase 2 (NEJM, 2023): 338 adults with obesity. Highest dose (12 mg weekly) → 24.2% mean weight loss at 48 weeks vs 2.1% for placebo. About 26% of high-dose subjects achieved ≥30% body weight reduction. (Jastreboff et al., NEJM 2023)
• Phase 3 TRIUMPH-4 (2025): Co-primary endpoints of weight loss and knee osteoarthritis pain. Results: 26.4–28.7% mean weight reduction at the highest dose in a larger Phase 3 population. This confirmed and extended the Phase 2 findings.
• MASLD Phase 2a (Nature Medicine, 2024): 82–86% relative reduction in liver fat by MRI at 48 weeks. Over 85% of subjects with steatosis achieved liver fat below the 5% diagnostic threshold. (Sanyal et al., Nature Medicine 2024)

Direct Comparison Table: Weight Loss Efficacy

Important caveat: these are cross-trial comparisons, not head-to-head. Trial populations, dose escalation schedules, lifestyle intervention intensity, and follow-up periods all differ. A head-to-head study between retatrutide and semaglutide has not been published as of April 2026.

Metabolic Effects Beyond Weight: What Else Changes

Weight loss is the headline metric, but researchers are increasingly interested in metabolic effects that go beyond the scale.

Liver Fat

This is where retatrutide’s glucagon receptor component creates the biggest separation from semaglutide. Semaglutide reduces liver fat meaningfully — GLP-1 agonism does improve hepatic steatosis through systemic insulin sensitization and weight loss. But the magnitude is modest compared to what the glucagon receptor adds.

Retatrutide’s Phase 2a MASLD trial showed 82–86% relative reduction in liver fat. For context, semaglutide’s comparable data shows 40–60% relative reduction in hepatic fat fraction in MASH trials. The glucagon receptor directly stimulates fatty acid oxidation in hepatocytes — a liver-specific mechanism that explains the gap.

Glycemic Control

Both peptides improve glycemic parameters through GLP-1-mediated insulin sensitization. Semaglutide has extensive HbA1c data across the SUSTAIN program (reductions of 1.5–1.8% in type 2 diabetes trials). Retatrutide’s Lancet Phase 2 diabetes trial showed comparable HbA1c improvements alongside the superior weight data.

Importantly, neither compound appears to cause significant hypoglycemia in clinical trials, because both rely on glucose-dependent insulin secretion mechanisms — insulin is only released when blood glucose is already elevated.

Energy Expenditure

Retatrutide has a mechanistic advantage here that semaglutide does not. Glucagon receptor activation in brown adipose tissue and the liver increases thermogenesis — the body burns more calories at rest. Semaglutide’s contribution to energy expenditure is largely indirect (the body burns fewer calories due to reduced appetite and food intake, but the basal metabolic rate reduction that accompanies weight loss is not counteracted).

Whether this thermogenic effect translates to clinically meaningful differences in lean mass preservation or long-term weight maintenance remains an active research question.

Cardiovascular Outcomes

This is semaglutide’s strongest advantage in the current evidence base. The SELECT trial — 17,604 patients, established CVD, no diabetes — showed a 20% reduction in MACE. That is a hard cardiovascular endpoint in the largest trial of its kind.

Retatrutide has a cardiovascular outcomes trial underway but no completed CVOT data. Whether triple agonism produces equivalent, superior, or inferior cardiovascular benefit compared to GLP-1 agonism alone remains unknown as of 2026.

Side Effect Profiles: How They Compare

Both compounds share the GLP-1 mechanism’s characteristic GI side effect profile. The comparison is broadly similar, with some nuances.

One area where GIP receptor co-agonism (present in retatrutide, absent in semaglutide) has shown benefit is GI tolerability: some research suggests that GIP receptor activation attenuates the nausea caused by GLP-1 agonism alone. Tirzepatide’s real-world GI tolerability profile has been somewhat better than expected for its weight loss magnitude, and researchers attribute part of this to the GIP component. Whether retatrutide’s triple mechanism produces a similar effect is an open question.

Dosing Differences in Research Protocols

Both peptides use once-weekly subcutaneous injection in clinical trials, with gradual dose escalation to improve tolerability. The escalation timelines differ:

The absolute dose numbers are not directly comparable — these molecules have different molecular weights and receptor potency profiles. The 12 mg retatrutide dose is not “five times stronger” than 2.4 mg semaglutide in any meaningful sense; the numbers simply reflect different pharmacological properties.

What Researchers Currently Prefer — and Why

The framing of “which peptide researchers prefer” depends heavily on the research question:

• Cardiovascular outcomes research: Semaglutide has the data. SELECT is a landmark trial. Researchers studying cardiovascular endpoints have a completed, peer-reviewed CVOT to reference.
• Maximum weight loss models: Retatrutide’s Phase 3 data at 26–29% suggests it may be the most potent weight reduction compound yet studied in a clinical setting.
• Liver disease (MASLD/NASH) models: Retatrutide’s 82–86% liver fat reduction data and 85%+ steatosis resolution rates are unmatched in the literature. The glucagon receptor mechanism is specific to hepatic lipid metabolism in a way semaglutide cannot replicate.
• Well-characterized safety profile: Semaglutide has years of post-marketing real-world data from Ozempic and Wegovy. Retatrutide’s longest dataset is 48–52 weeks in controlled trials.
• Energy expenditure and thermogenesis: Retatrutide’s glucagon component makes it the compound of choice for researchers interested in metabolic rate changes separate from caloric restriction.

Summary of Key Research References